Created in 2010
Ysopia Bioscience (previously LNC Therapeutics)
YSOPIA Bioscience (previously LNC Therapeutics) is a French biotech company specializing in the research and development of therapeutic innovations harnessing the potential of the gut microbiome.
Founded in 2010, it is developing a new class of drugs—single strain Live Biotherapeutic Products (LBPs). Its most advanced development program,Yso1, recently obtained the U.S. Food and Drug Administration approval to start a Phase 1 clinical trial in obesity and associated metabolic diseases. Its portfolio also includes 3 other innovative programs in chronic indications with substantial unmet medical needs.
Supported by leading venture capital investors, such as Seventure Partners, and family offices, YSOPIA Bioscience has established collaborative projects worldwide with renowned scientific experts to maintain the highest standards in its development of innovative biotherapeutics.